JSKN003-101 First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors
Status:
Not yet recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
This study is an open-label, multicenter, first-in-human, Phase I, dose escalation study to
evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of JSKN003 in
subjects with advanced inoperable or metastatic solid malignant tumors that are expected to
be HER2 expression.